Results 91 to 100 of about 26,634 (259)
„Zalety” technologii rozproszonych rejestrów a rozporządzenie pilotażowe DLT [PDF]
The aim of the DLT Pilot Regime is to allow for the development of crypto-assets that qualify as financial instruments and for the development of distributed ledger technology.
Tomczak, Tomasz
core +1 more source
Assessment criteria for DLT platforms [PDF]
, 2020 Informe técnicoEspecificación técnica de la Unión Internacional de Telecomunicaciones para evaluar la arquitectura de redes DLTITU-T Tecnical Specification to assess DLT network reference architectureinfo:eu-repo/semantics ...
Ibáñez Jiménez, Javier Wenceslao +2 more
core
Precision Radiation Oncology, EarlyView.RT‐immunotherapy synergy for thoracic tumors relies on precise target delineation to protect immune components. IFI, reduced volumes, and optimized positioning minimize damage, while multimodal imaging, DL, PBT, and FLASH‐RT enhance control. These innovations shift RT to an immune‐centric model, improving lung and esophageal cancer outcomes.
Xiaoying Chen +3 more
wiley +1 more source
IVyTools: Space–Time Image Velocimetry for Streamflow
River Research and Applications, EarlyView.ABSTRACT Accurate streamflow measurements are essential for hydrologic monitoring, flood forecasting, and water resource management. Traditional in situ methods, although reliable, are often impractical or unsafe during flood conditions or at inaccessible locations. Image velocimetry techniques offer a potential non‐contact alternative, yet operational
Frank L. Engel +3 more
wiley +1 more source
Advances in γδ T Cells: Cutaneous Biology and Therapeutic Potential for Skin Neoplasms
The Journal of Dermatology, EarlyView.ABSTRACT γδ T cells represent an increasingly important subset of T lymphocytes in the immune response to cancer and as a platform for novel immunotherapies. The aim of this review is to synthesize recent insights into the biology and advances in therapeutic applications of γδ T cells in cutaneous malignancies, especially melanoma, within a framework ...
Simo Du +9 more
wiley +1 more source
The effect of addback statutes on CEO compensation
Accounting &Finance, Volume 65, Issue 1, Page 793-818, March 2025.Abstract Exploiting the adoption of addback statutes, which occurred at different times, as exogenous shocks to corporate taxable income, we examine the effect of tax policy changes on the compensation of chief executive officers (CEOs). We provide evidence that CEOs of firms headquartered in states affected by addback statutes experienced a decrease ...
Karel Hrazdil +3 more
wiley +1 more source
Asia-Pacific Journal of Financial Studies, EarlyView.Abstract This study develops an explainable machine learning model to predict cryptocurrency delistings using Binance data. It combines quantitative indicators (price, volume) with qualitative data from real‐time news and Reddit. Latent Dirichlet Allocation (LDA) is used to extract topic trends and community reactions, which are transformed into time ...
Sungju Yang, Hunyeong Kwon
wiley +1 more source
Clinical Case ReportsSubglottic stenosis after double‐lumen tube (DLT) intubation is more likely to occur when an oversized DLT, specifically a 35 Fr DLT, is used in older, shorter women. Reintubation in such cases is challenging and may cause additional traumatic laryngitis.
Masami Suzuki, Naohiro Yoshida
doaj +1 more source
Pre‐Seasonal Treatment With Recombinant Carrier‐Based Birch Vaccine Improves Birch Pollen Allergy
Allergy, EarlyView.We conducted a two stage SCIT trial with GNR‐127 containing a recombinant fusion protein consisting of Bet v 1 and Mal d 1‐derived peptides fused to PreS from HBV. Stage 1 identified two safe maximum tolerated doses (40 μg and 80 μg). In the following Stage 2, five preseasonal injections were well tolerated, induced dose‐dependent allergen‐specific IgG,
Musa R. Khaitov +43 more
wiley +1 more source
British Journal of Haematology, EarlyView.Summary Glofitamab was investigated with obinutuzumab/rituximab plus cyclophosphamide, doxorubicin, vincristine and prednisone (G/R‐CHOP) in patients with relapsed/refractory B‐cell non‐Hodgkin lymphoma (B‐NHL) who had ≥1 prior obinutuzumab/rituximab‐containing therapy (NCT03467373). The primary end‐point was to determine the optimal biological dose of
William Townsend +16 more
wiley +1 more source